Literature DB >> 9552717

Antibiotic resistance in Escherichia coli isolated from blood and cerebrospinal fluid: a 6-year study of isolates from patients in England and Wales.

E J Threlfall1, T Cheasty, A Graham, B Rowe.   

Abstract

A study of the incidence of resistance to antimicrobial drugs in Escherichia coli from blood and CSF made in England and Wales in the 6-year period 1991 1996 has demonstrated a significant increase in the incidence of strains resistant to ampicillin and ciprofloxacin, two antibiotics used for first-line therapy of invasive disease. In particular, there has been a dramatic change in the occurrence of isolates with low level or high level resistance to ciprofloxacin; over 90% of isolates in the high level group were also resistant to at least four other antimicrobials. Physicians in England and Wales should be aware that there is now an increasing possibility of treatment failures when ciprofloxacin is used for the treatment of invasive E. coli infections.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9552717     DOI: 10.1016/s0924-8579(97)00055-1

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  3 in total

1.  Antimicrobial resistance in enteric pathogens isolated from Minnesota pigs from 1995 to 2004.

Authors:  Yashpal S Malik; Yogesh Chander; Karen Olsen; Sagar M Goyal
Journal:  Can J Vet Res       Date:  2011-04       Impact factor: 1.310

2.  Trends in fluoroquinolone (ciprofloxacin) resistance in enterobacteriaceae from bacteremias, England and Wales, 1990-1999.

Authors:  David M Livermore; Dorothy James; Mark Reacher; Catriona Graham; Thomas Nichols; Peter Stephens; Alan P Johnson; Robert C George
Journal:  Emerg Infect Dis       Date:  2002-05       Impact factor: 6.883

3.  The GimA locus of extraintestinal pathogenic E. coli: does reductive evolution correlate with habitat and pathotype?

Authors:  Timo Homeier; Torsten Semmler; Lothar H Wieler; Christa Ewers
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.